CDT Equity Inc.

CDT Healthcare Biotechnology

In the quarter to June 2026, EPS grew 98.0% and free cash flow grew 78.9%, each against the same quarter a year earlier.

0.24 0.03 +14.29%
Market cap
$240.0K
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Dec '17 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Current Ratio
— 0.54 0.15 3.18 0.25 0.34
Net Debt/EBITDA
— 11.05 (0.47) 0.88 0.04 0.05
Debt/Equity
— 0.00 (0.18) 0.00 0.00 0.00
ROE
— 0.00% 97.08% 10.15% 491.09% 561.83%
ROA
— (4.13%) (4,481.43%) (14.80%) (311.85%) (796.99%)
ROIC
— 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
— 4.98% 138.47% (13.61%) 222.92% 479.98%
Free Cash Flow per Share
— 0.00 (0.06) (11.53) 0.00 (163,630.00)
Book value per Share
— 0.01 (0.27) (0.68) 0.00 (71,700.00)
Free Cash Flow
— (0.01) (2.27) (7.72) (9.73) (16.36)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Oct 2026